- Home
- AUPH vs RLAY Comparison
AUPH vs RLAY Comparison
Compare AUPH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | RLAY |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AUPH | RLAY |
|---|---|---|
| Price | $15.83 | $8.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $17.25 | $16.00 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $265,808,000.00 | $8,355,000.00 |
| Revenue This Year | $21.22 | $20.47 |
| Revenue Next Year | $15.40 | N/A |
| P/E Ratio | $28.70 | ★ N/A |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $6.55 | $1.78 |
| 52 Week High | $16.48 | $9.04 |
Technical Indicators
Market Signals| Indicator | AUPH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 58.50 | 58.35 |
| Support Level | $15.57 | $7.42 |
| Resistance Level | $16.07 | $9.04 |
| Average True Range (ATR) | 0.49 | 0.47 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 66.17 | 42.82 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).